Landscape of KRAS mutations and targeted therapies in colorectal cancer mapped in new study

A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has ...

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its ...

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

For more details about SABCS please visit: https://www.sabcs.org/.
BC Technology

Rakovina Therapeutics Reports Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors

Rakovina Therapeutics Inc., a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, has announced impressive results from its AI-enabled ATR program at the recent ...

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

Pharmacokinetic profiling in mice following a single 5 mg/kg intraperitoneal dose revealed favorable tolerability, metabolic stability in human liver microsomes, and measurable CNS exposure, ...
European Medical Journal

Evolving the Future of Breast Cancer Care: An Interview with Komal Jhaveri

Komal Jhaveri - Breast Medical Oncologist and Early Drug Development Specialist, Memorial Sloan Kettering Cancer Center, New York, ...
The Malaysian Reserve

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology ...

Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a ...

Celcuity Inc.: Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion ...
C&EN

Naringenin Alleviates the Autophagy-Associated AMPK-Akt/mTOR Pathway to Regulate Inflammation and Barrier Function, Decreasing DSS-Induced Intestinal Fibrosis

Guangxi Key Laboratory of Environmental Exposureomics and Entire Lifecycle Health, Guilin Medical University, No. 1, Zhiyuan Road, Guangxi, Guilin 541100, China South Asia Branch of National ...
IEEE

The binding affinity prediction of PI3K / Akt / mTOR signaling pathway proteins with drugs based on deep learning method

Abstract: Human papillomavirus (HPV) infection is linked to several diseases, the most prominent of which are cervical cancer and genital condyloma acuminatum. PI3K-Akt-mTOR signaling pathway is one ...